Clinical Research Directory
Browse clinical research sites, groups, and studies.
Home Reported Outcomes in C3G Study
Sponsor: Novartis Pharmaceuticals
Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced by C3 glomerulopathy (C3G) patients and their caregivers. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-reported outcome (PRO) measures (collected at baseline and monthly), the study seeks to establish a new real-world data (RWD) source to understand symptom variability and HRQoL as reported by C3G patients and caregivers, including those taking iptacopan
Official title: A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in C3 Glomerulopathy (C3G) in the US
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2025-04-07
Completion Date
2026-04-30
Last Updated
2025-06-19
Healthy Volunteers
No
Conditions
Locations (1)
Novartis Investigative Site
East Hanover, New Jersey, United States